Russia points to China to vindicate vaccine stance

28 August 2020

When Russia chose to approve the Moscow-developed Sputnik V vaccine for COVID-19 this month, more than a few eyebrows were raised in the western world, in particular due to the absence of Phase III data.

But the approach of approving a vaccine without the usual conclusive late-stage data has been vindicated by China adopting the same strategy, says a Moscow official.

"Many countries are following Russia's approach" Reuters has reported that Sinovac Biotech’s (Nasdaq: SVA) coronavirus vaccine candidate CoronaVac was approved in July for emergency use as part of a program in China to vaccinate high-risk groups.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK